NYSE:NVS - Novartis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$75.06 +1.08 (+1.46 %)
(As of 06/24/2018 05:02 AM ET)
Previous Close$75.06
Today's Range$74.81 - $75.47
52-Week Range$73.21 - $94.19
Volume1.74 million shs
Average Volume1.60 million shs
Market Capitalization$171.45 billion
P/E Ratio15.60
Dividend Yield2.58%
Beta0.76
Novartis logoNovartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVS
CUSIPN/A
Phone41-61-324-1111

Debt

Debt-to-Equity Ratio0.33
Current Ratio1.17
Quick Ratio0.91

Price-To-Earnings

Trailing P/E Ratio15.60
Forward P/E Ratio14.38
P/E Growth1.62

Sales & Book Value

Annual Sales$49.11 billion
Price / Sales3.54
Cash Flow$7.6436 per share
Price / Cash9.82
Book Value$32.03 per share
Price / Book2.34

Profitability

EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Net Margins16.04%
Return on Equity16.23%
Return on Assets8.69%

Miscellaneous

Employees121,597
Outstanding Shares2,317,460,000

The Truth About Cryptocurrencies

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How will Novartis' stock buyback program work?

Novartis declared that its board has approved a stock repurchase plan on Saturday, April 8th 2017, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its shares are undervalued.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Thursday, April, 19th. The company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.03. The business had revenue of $12.69 billion for the quarter, compared to analyst estimates of $12.45 billion. Novartis had a return on equity of 16.23% and a net margin of 16.04%. Novartis's revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.13 earnings per share. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, July, 18th 2018. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

11 brokerages have issued 12-month price targets for Novartis' shares. Their forecasts range from $82.25 to $91.00. On average, they expect Novartis' stock price to reach $87.75 in the next year. View Analyst Ratings for Novartis.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 53)
  • Mr. Steven Baert, Head of HR (Age 44)
  • Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)
  • Mr. F. Michael Ball, CEO, Alcon (Age 63)

Has Novartis been receiving favorable news coverage?

News stories about NVS stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Novartis earned a media sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the company an impact score of 46.66 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Novartis' major shareholders?

Novartis' stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (0.64%), Loomis Sayles & Co. L P (0.34%), Fisher Asset Management LLC (0.30%), Northern Trust Corp (0.18%), Thomaspartners Inc. (0.17%) and BlackRock Inc. (0.17%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., The Manufacturers Life Insurance Company, Reynders McVeigh Capital Management LLC, BlackRock Inc., Manning & Napier Group LLC, Federated Investors Inc. PA, Blair William & Co. IL and Senzar Asset Management LLC. View Insider Buying and Selling for Novartis.

Which institutional investors are buying Novartis stock?

NVS stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Rockefeller Capital Management L.P., Loomis Sayles & Co. L P, Boston Partners, Millennium Management LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC and Sei Investments Co.. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $75.06.

How big of a company is Novartis?

Novartis has a market capitalization of $171.45 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  342 (Vote Outperform)
Underperform Votes:  399 (Vote Underperform)
Total Votes:  741
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.